BEACON : A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Targeting the C1 Subtype of High Grade Serous Ovarian Cancer

Female<br/>OnlyGender Female
Only

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Female Reproductive<br/>System CancersCancer LocationFemale Reproductive
System Cancers

Systemic therapy | Female reproductive organsFallopian tube,Ovary,Peritoneal

Trial Overview Read MoreRead more

This phase II trial is evaluating the combination of three immunotherapy drugs (Atezolizumab, Bevacizumab and Cobimetinib) in patients diagnosed with High Grade Serous Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer.
 

This trial is treating patients with High Grade Serous Ovarian Cancer, Fallopian Tube Cancer Primary Peritoneal Carcinoma.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Targeting the C1 Subtype of High Grade Serous Ovarian Cancer

Other Non-Commercial Sponsor

Peter MacCallum Cancer Centre

Summary

Participants will receive intravenous Bevacizumab (5mg/kg) every two weeks, intravenous Atezolizumab (840mg) every two weeks from Cycle two onwards and Cobimetinib (60mg per day) every day for 21 days.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next